Antimicrobial resistance in : Global surveillance and a call for international collaborative action

1. Newman L, Rowley J, Vander Hoorn S, Wijesooriya NS, Unemo M, Low N, et al. Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting. PLoS ONE. 2015; 10(12):e0143304. doi: 10.1371/journal.pone.0143304 26646541

2. Vos T, Barber RM, Bell B, Bertozzi-Villa A, Biryukov S, Bolliger I, et al.; Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015; 386(9995):743–800. doi: 10.1016/S0140-6736(15)60692-4 26063472

3. Murray CJ, Barber RM, Foreman KJ, Abbasoglu Ozgoren A, Abd-Allah F, Abera SF, et al. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: Quantifying the epidemiological transition. Lancet. 2015; 386(10009):2145–2191. doi: 10.1016/S0140-6736(15)61340-X 26321261

4. Cohen MS, Hoffman IF, Royce RA, Kazembe P, Dyer JR, Daly CC, et al.; AIDSCAP Malawi Research Group. Reduction of concentration of HIV-1 in semen after treatment of urethritis: Implications for prevention of sexual transmission of HIV-1. Lancet. 1997; 349(9069):1868–1873. 9217758

5. World Health Organization (WHO). Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae. Geneva: WHO; 2012. Available from: http://www.who.int/reproductivehealth/publications/rtis/9789241503501/en/

6. Unemo M, Shafer WM. Antimicrobial resistance in Neisseria gonorrhoeae in the 21st Century: Past, evolution, and future. Clin Microbiol Rev. 2014; 27(3):587–613. doi: 10.1128/CMR.00010-14 24982323

7. Unemo M. Current and future antimicrobial treatment of gonorrhoea–the rapidly evolving Neisseria gonorrhoeae continues to challenge. BMC Infect Dis. 2015; 15:364. doi: 10.1186/s12879-015-1029-2 26293005

8. Unemo M, Jensen JS. Antimicrobial-resistant sexually transmitted infections: Gonorrhoea and Mycoplasma genitalium. Nat Rev Urol. 2017; 14(3):139–152. doi: 10.1038/nrurol.2016.268 28072403

9. World Health Organization (WHO). WHO guidelines for the treatment of Neisseria gonorrhoeae. Geneva: WHO; 2016. Available from: http://www.who.int/reproductivehealth/publications/rtis/gonorrhoea-treatment-guidelines/en/

10. Workowski KA, Bolan GA; Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015; 64(RR-03):1–137. 26042815

11. Bignell C, Unemo M; European STI Guidelines Editorial Board. European guideline on the diagnosis and treatment of gonorrhoea in adults. Int J STD AIDS. 2012; 24(2):85–92. doi: 10.1177/0956462412472837 24400344

12. Romanowski B, Robinson J, Wong T. Gonococcal infections chapter. In: Canadian guidelines on sexually transmitted infections. Ottawa, ON: Public Health Agency of Canada; 2013. Available from: www.phac-aspc.gc.ca/std-mts/sti-its/cgsti-ldcits/assets/pdf/section-5-6-eng.pdf

13. Australasian Sexual Health Alliance (ASHA). Gonorrhoea. In: Australian STI management guidelines for use in primary care [website]. ASHA; 2016. Available from: www.sti.guidelines.org.au/sexually-transmissible-infections/gonorrhoea#management

14. World Health Organization (WHO). Global health sector strategy on sexually transmitted infections 2016–2021: Towards ending STIs. Geneva: WHO; 2016. Available from: http://www.who.int/reproductivehealth/publications/rtis/ghss-stis/en/

15. Ndowa F, Lusti-Narasimhan M, Unemo M. The serious threat of multidrug-resistant and untreatable gonorrhoea: The pressing need for global action to control the spread of antimicrobial resistance, and mitigate the impact on sexual and reproductive health. Sex Transm Infect. 2012; 88(5):317–318. doi: 10.1136/sextrans-2012-050674 22798629

16. World Health Organization (WHO). Global action plan on antimicrobial resistance. Geneva: WHO; 2015. Available from: http://www.who.int/antimicrobial-resistance/publications/global-action-plan/en/

17. World Health Organization (WHO). Global surveillance network for gonococcal antimicrobial susceptibility. Geneva: WHO; 1990. WHO/VDT/90-452. Available from: http://apps.who.int/medicinedocs/documents/s16348e/s16348e.pdf

18. Joint United Nations Programme on HIV/AIDS (UNAIDS), World Health Organization (WHO). Sexually transmitted diseases: Policies and principles for prevention and care. Geneva; UNAIDS, WHO; 1999. UNAIDS/01.11e. Available from: http://data.unaids.org/publications/irc-pub04/una97-6_en.pdf

19. Unemo M, Fasth O, Fredlund H, Limnios A, Tapsall J. Phenotypic and genetic characterization of the 2008 WHO Neisseria gonorrhoeae reference strain panel intended for global quality assurance and quality control of gonococcal antimicrobial resistance surveillance for public health purposes. J Antimicrob Chemother. 2009; 63(6):1142–1151. doi: 10.1093/jac/dkp098 19318360

20. Unemo M, Golparian D, Sánchez-Busó L, Grad Y, Jacobsson S, Ohnishi M, et al. The novel 2016 WHO Neisseria gonorrhoeae reference strains for global quality assurance of laboratory investigations: Phenotypic, genetic and reference genome characterization. J Antimicrob Chemother. 2016; 71(11):3096–3108. doi: 10.1093/jac/dkw288 27432602

21. Spiteri G, Cole M, Unemo M, Hoffmann S, Ison C, van de Laar M. The European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP)–a sentinel approach in the European Union (EU)/European Economic Area (EEA). Sex Transm Infect. 2013; 89(Suppl 4):iv16–iv18. doi: 10.1136/sextrans-2013-051117 24243874

22. Cole MJ, Spiteri G, Jacobsson S, Pitt R, Grigorjev V, Unemo M; Euro-GASP Network. Is the tide turning again for cephalosporin resistance in Neisseria gonorrhoeae in Europe? Results from the 2013 European surveillance. BMC Infect Dis. 2015; 15(1):321. doi: 10.1186/s12879-015-1013-x 26259560

23. Kirkcaldy RD, Kidd S, Weinstock HS, Papp JR, Bolan GA. Trends in antimicrobial resistance in Neisseria gonorrhoeae in the USA: The Gonococcal Isolate Surveillance Project (GISP), January 2006 –June 2012. Sex Transm Infect. 2013; 89(Suppl 4):iv5–10. doi: 10.1136/sextrans-2013-051162 24243881

24. Kirkcaldy RD, Harvey A, Papp JR, Del Rio C, Soge OO, Holmes KK, et al. Neisseria gonorrhoeae antimicrobial susceptibility surveillance–The Gonococcal Isolate Surveillance Project, 27 sites, United States, 2014. MMWR Surveill Summ. 2016; 65 (7):1–19. doi: 10.15585/mmwr.ss6507a1 27414503

25. Martin I, Sawatzky P, Liu G, Allen V, Lefebvre B, Hoang L, et al. Decline in decreased cephalosporin susceptibility and increase in azithromycin resistance in Neisseria gonorrhoeae, Canada. Emerg Infect Dis. 2016; 22(1):65–67. doi: 10.3201/eid2201.151247 26689114

26. Lahra MM; Australian Gonococcal Surveillance Programme. Australian Gonococcal Surveillance Programme annual report, 2014. Commun Dis Intell Q Rep. 2015; 39(3):E347–354. 26620348

27. Town K, Obi C, Quaye N, Chisholm S, Hughes G; GRASP Collaborative Group. Drifting towards ceftriaxone treatment failure in gonorrhoea: Risk factor analysis of data from the Gonococcal Resistance to Antimicrobials Surveillance Programme in England and Wales. Sex Transm Infect. 2017; 93(1):39–45. doi: 10.1136/sextrans-2016-052583 27382010

28. Unemo M, Ison CA, Cole M, Spiteri G, van de Laar M, Khotenashvili L. Gonorrhoea and gonococcal antimicrobial resistance surveillance networks in the WHO European Region, including the independent countries of the former Soviet Union. Sex Transm Infect. 2013; 89(Suppl 4):iv42–iv46. doi: 10.1136/sextrans-2012-050909 24243879

29. Lahra MM, Lo YR, Whiley DM. Gonococcal antimicrobial resistance in the Western Pacific Region. Sex Transm Infect. 2013; 89(Suppl 4):iv19–23. doi: 10.1136/sextrans-2012-050906 24243875

30. Dillon JA, Trecker MA, Thakur SD; Gonococcal Antimicrobial Surveillance Program Network in Latin America and the Caribbean 1990–2011. Two decades of the gonococcal antimicrobial surveillance program in South America and the Caribbean: Challenges and opportunities. Sex Transm Infect. 2013; 89(Suppl 4):iv36–iv41. doi: 10.1136/sextrans-2012-050905

31. Thakur SD, Araya P, Borthagaray G, Galarza P, Hernandez AL, Payares D, et al. Resistance to ceftriaxone and azithromycin in Neisseria gonorrhoeae isolates from 7 countries of South America and the Caribbean: 2010–2011. Sex Transm Dis. 2017; 44(3):157–160. doi: 10.1097/OLQ.0000000000000587 28178114

32. Ndowa FJ, Francis JM, Machiha A, Faye-Kette H, Fonkoua MC. Gonococcal antimicrobial resistance: Perspectives from the African region. Sex Transm Infect. 2013; 89(Suppl 4):iv11–iv15. doi: 10.1136/sextrans-2012-050907 24243873

33. UNAIDS/WHO Working Group on Global HIV/AIDS and STI Surveillance. Strategies and laboratory methods for strengthening surveillance of sexually transmitted infections 2012. Geneva: World Health Organization; 2012. Available from: http://apps.who.int/iris/bitstream/10665/75729/1/9789241504478_eng.pdf

34. Bala M, Kakran M, Singh V, Sood S, Ramesh V; Members of WHO GASP SEAR Network. Monitoring antimicrobial resistance in Neisseria gonorrhoeae in selected countries of the WHO South-East Asia Region between 2009 and 2012: A retrospective analysis. Sex Transm Infect. 2013; 89(Suppl 4):iv28–35. doi: 10.1136/sextrans-2012-050904 24243876

35. European Centre for Disease Prevention and Control (ECDC). ECDC surveillance report: Gonococcal antimicrobial susceptibility surveillance in Europe 2014. Stockholm: ECDC; 2016. Available from: http://ecdc.europa.eu/en/publications/Publications/gonococcal-antimicrobial-susceptibility-surveillance-Europe-2014.pdf

36. Yokoi S, Deguchi T, Ozawa T, Yasuda M, Ito S, Kubota Y, et al. Threat to cefixime treatment for gonorrhea. Emerg Infect Dis. 2007; 13(8):1275–1277. doi: 10.3201/eid1308.060948 17953118

37. Deguchi T, Yasuda M, Yokoi S, Ishida K, Ito M, Ishihara S, et al. Treatment of uncomplicated gonococcal urethritis by double-dosing of 200 mg cefixime at a 6-h interval. J Infect Chemother. 2003; 9(1):35–39. doi: 10.1007/s10156-002-0204-8 12673405

38. Unemo M, Golparian D, Syversen G, Vestrheim DF, Moi H. Two cases of verified clinical failures using internationally recommended first-line cefixime for gonorrhoea treatment, Norway, 2010. Euro Surveill. 2010; 15(47)

39. Ison CA, Hussey J, Sankar KN, Evans J, Alexander S. Gonorrhoea treatment failures to cefixime and azithromycin in England. Euro Surveill. 2011; 16(14)

40. Unemo M, Golparian D, Stary A, Eigentler A. First Neisseria gonorrhoeae strain with resistance to cefixime causing gonorrhoea treatment failure in Austria, 2011. Euro Surveill. 2011; 16(43)

41. Unemo M, Golparian D, Nicholas R, Ohnishi M, Gallay A, Sednaoui P. High-level cefixime- and ceftriaxone-resistant N. gonorrhoeae in France: Novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother. 2012; 56(3):1273–1280. doi: 10.1128/AAC.05760-11 22155830

42. Allen VG, Mitterni L, Seah C, Rebbapragada A, Martin IE, Lee C, et al. Neisseria gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada. JAMA. 2013; 309(2):163–170. doi: 10.1001/jama.2012.176575 23299608

43. Singh AE, Gratrix J, Martin I, Friedman DS, Hoang L, Lester R, et al. Gonorrhea treatment failures with oral and injectable expanded spectrum cephalosporin monotherapy vs dual therapy at 4 Canadian sexually transmitted infection clinics, 2010–2013. Sex Transm Dis. 2015; 42(6):331–336. doi: 10.1097/OLQ.0000000000000280 25970311

44. Lewis DA, Sriruttan C, Müller EE, Golparian D, Gumede L, Fick D, et al. Phenotypic and genetic characterization of the first two cases of extended-spectrum cephalosporin resistant Neisseria gonorrhoeae infection in South Africa and association with cefixime treatment failure. J Antimicrob Chemother. 2013; 68(6):1267–1270. doi: 10.1093/jac/dkt034 23416957

45. Ohnishi M, Golparian D, Shimuta K, Saika T, Hoshina S, Iwasaku K, et al. Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea? Detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob Agents Chemother. 2011; 55(7):3538–3545. doi: 10.1128/AAC.00325-11 21576437

46. Tapsall J, Read P, Carmody C, Bourne C, Ray S, Limnios A, et al. Two cases of failed ceftriaxone treatment in pharyngeal gonorrhoea verified by molecular microbiological methods. J Med Microbiol. 2009; 58(Pt 5):683–687. doi: 10.1099/jmm.0.007641-0 19369534

47. Chen YM, Stevens K, Tideman R, Zaia A, Tomita T, Fairley CK, et al. Failure of ceftriaxone 500 mg to eradicate pharyngeal gonorrhoea, Australia. J Antimicrob Chemother. 2013; 68(6):1445–1447. doi: 10.1093/jac/dkt017 23390207

48. Read PJ, Limnios EA, McNulty A, Whiley D, Lahra LM. One confirmed and one suspected case of pharyngeal gonorrhoea treatment failure following 500 mg ceftriaxone in Sydney, Australia. Sex Health. 2013; 10(5):460–462. doi: 10.1071/SH13077 24028864

49. Unemo M, Golparian D, Hestner A. Ceftriaxone treatment failure of pharyngeal gonorrhoea verified by international recommendations, Sweden, July 2010. Euro Surveill. 2011; 16(6):1–3.

50. Golparian D, Ohlsson A, Janson H, Lidbrink P, Richtner T, Ekelund O, et al. Four treatment failures of pharyngeal gonorrhoea with ceftriaxone (500 mg) or cefotaxime (500 mg), Sweden, 2013 and 2014. Euro Surveill. 2014; 19(30)

51. Unemo M, Golparian D, Potočnik M, Jeverica S. Treatment failure of pharyngeal gonorrhoea with internationally recommended first-line ceftriaxone verified in Slovenia, September 2011. Euro Surveill. 2012; 17(25):1–4.

52. Fifer H, Natarajan U, Jones L, Alexander S, Hughes G, Golparian D, et al. Failure of dual antimicrobial therapy in treatment of gonorrhea. N Engl J Med. 2016; 374(25):2504–2506. doi: 10.1056/NEJMc1512757 27332921

53. Cámara J, Serra J, Ayats J, Bastida T, Carnicer-Pont D, Andreu A, et al. Molecular characterization of two high-level ceftriaxone-resistant Neisseria gonorrhoeae isolates detected in Catalonia, Spain. J Antimicrob Chemother. 2012; 67(8):1858–1860. doi: 10.1093/jac/dks162 22566592

54. Tapsall JW, Ndowa F, Lewis DA, Unemo M. Meeting the public health challenge of multidrug- and extensively drug-resistant Neisseria gonorrhoeae. Expert Rev Anti Infect Ther. 2009; 7(7):821–834. doi: 10.1586/eri.09.63 19735224

55. Progress report of the implementation of the global strategy for prevention and control of sexually transmitted infections: 2006–2015. Document for the World Health Assembly. Geneva: World Health Organization; 2015. Available from: http://www.who.int/reproductivehealth/publications/rtis/STI-progress.pdf

56. Lewis DA. Will targeting oropharyngeal gonorrhoea delay the further emergence of drug-resistant Neisseria gonorrhoeae strains? Sex Transm Infect. 2015; 91(4):234–237. doi: 10.1136/sextrans-2014-051731 25911525

57. Allan-Blitz LT, Humphries RM, Hemarajata P, Bhatti A, Pandori MW, Siedner MJ, et al. Implementation of a rapid genotypic assay to promote targeted ciprofloxacin therapy of Neisseria gonorrhoeae in a large health system. Clin Infect Dis. 2017; 64(9):1268–1270. doi: 10.1093/cid/ciw864 28034887

58. Goire N, Lahra MM, Chen M, Donovan B, Fairley CK, Guy R, et al. Molecular approaches to enhance surveillance of gonococcal antimicrobial resistance. Nat Rev Microbiol. 2014; 12(3):223–229. doi: 10.1038/nrmicro3217 24509781

59. Low N, Unemo M. Molecular tests for the detection of antimicrobial resistant Neisseria gonorrhoeae: When, where, and how to use? Curr Opin Infect Dis. 2016; 29(1):45–51. doi: 10.1097/QCO.0000000000000230 26658656

60. Chow EP, Howden BP, Walker S, Lee D, Bradshaw CS, Chen MY, et al. Antiseptic mouthwash against pharyngeal Neisseria gonorrhoeae: A randomised controlled trial and an in vitro study. Sex Transm Infect. 2017; 93(2):88–93. doi: 10.1136/sextrans-2016-052753 27998950

61. Jerse AE, Deal CD. Vaccine research for gonococcal infections: Where are we? Sex Transm Infect. 2013; 89(Suppl 4):iv63–68. doi: 10.1136/sextrans-2013-051225 24243883

62. Edwards JL, Jennings MP, Apicella MA, Seib KL. Is gonococcal disease preventable? The importance of understanding immunity and pathogenesis in vaccine development. Crit Rev Microbiol. 2016; 42(6):928–941. doi: 10.3109/1040841X.2015.1105782 26805040

63. Demczuk W, Sidhu S, Unemo M, Whiley DM, Allen VG, Dillon JR, et al. Neisseria gonorrhoeae Sequence Typing for Antimicrobial Resistance (NG-STAR): A novel antimicrobial resistance multilocus typing scheme for tracking the global dissemination of N. gonorrhoeae strains. J Clin Microbiol. 2017; 55(5):1454–1468. doi: 10.1128/JCM.00100-17 28228492

64. Demczuk W, Lynch T, Martin I, Van Domselaar G, Graham M, Bharat A, et al. Whole-genome phylogenomic heterogeneity of Neisseria gonorrhoeae isolates with decreased cephalosporin susceptibility collected in Canada between 1989 and 2013. J Clin Microbiol. 2015; 53(1):191–200. doi: 10.1128/JCM.02589-14 25378573

65. Demczuk W, Martin I, Peterson S, Bharat A, Van Domselaar G, Graham M, et al. Genomic epidemiology and molecular resistance mechanisms of azithromycin-resistant Neisseria gonorrhoeae in Canada from 1997 to 2014. J Clin Microbiol. 2016; 54(5):1304–1313. doi: 10.1128/JCM.03195-15 26935729

66. Grad YH, Kirkcaldy RD, Trees D, Dordel J, Harris SR, Goldstein E, et al. Genomic epidemiology of Neisseria gonorrhoeae with reduced susceptibility to cefixime in the USA: A retrospective observational study. Lancet Infect Dis. 2014; 14(3):220–226. doi: 10.1016/S1473-3099(13)70693-5 24462211

67. Jacobsson S, Golparian D, Cole M, Spiteri G, Martin I, Bergheim T, et al. WGS analysis and molecular resistance mechanisms of azithromycin-resistant (MIC >2 mg/L) Neisseria gonorrhoeae isolates in Europe from 2009 to 2014. J Antimicrob Chemother. 2016; 71(11):3109–3116. doi: 10.1093/jac/dkw279 27432597

68. De Silva D, Peters J, Cole K, Cole MJ, Cresswell F, Dean G, et al. Whole-genome sequencing to determine transmission of Neisseria gonorrhoeae: An observational study. Lancet Infect Dis. 2016; 16(11):1295–1303. doi: 10.1016/S1473-3099(16)30157-8 27427203

69. Ezewudo MN, Joseph SJ, Castillo-Ramirez S, Dean D, Del Rio C, Didelot X, et al. Population structure of Neisseria gonorrhoeae based on whole genome data and its relationship with antibiotic resistance. PeerJ. 2015; 3:e806. doi: 10.7717/peerj.806 25780762

70. Vidovic S, Caron C, Taheri A, Thakur SD, Read TD, Kusalik A, et al. Using crude whole-genome assemblies of Neisseria gonorrhoeae as a platform for strain analysis: Clonal spread of gonorrhea infection in Saskatchewan, Canada. J Clin Microbiol. 2014; 52(10):3772–3776. doi: 10.1128/JCM.01502-14 25056324

71. Eyre DW, De Silva D, Cole K, Peters J, Cole MJ, Grad YH, et al. WGS to predict antibiotic MICs for Neisseria gonorrhoeae. J Antimicrob Chemother. 2017; 10. doi: 10.1093/jac/dkx067 28333355